Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1384&sort=-approved
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-approved", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-approved", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1385&sort=-approved", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=-approved" }, "data": [ { "type": "Grant", "id": "12269", "attributes": { "award_id": "1OT2OD036445-01", "title": "The Illinois Precision Medicine Consortium (IPMC) All of Us Research Program Site", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 28152, "first_name": "Maria", "last_name": "Lopez-class", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-01", "end_date": "2024-08-31", "award_amount": 12060000, "principal_investigator": { "id": 22242, "first_name": "Habibul", "last_name": "Ahsan", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 27952, "first_name": "Philip", "last_name": "Greenland", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28153, "first_name": "Briseis A", "last_name": "Aschebrook-Kilfoy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28154, "first_name": "Catherine Hanson", "last_name": "Balthazar", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28155, "first_name": "Martha L", "last_name": "Daviglus", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28156, "first_name": "JOYCE", "last_name": "HO", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28157, "first_name": "Amber", "last_name": "Pirzada", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28158, "first_name": "Tonya", "last_name": "Roberson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28159, "first_name": "Alan R", "last_name": "Sanders", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28160, "first_name": "Raj C", "last_name": "Shah", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28161, "first_name": "Marcelo Bento", "last_name": "Soares", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "1.1. ABSTRACT The first 7 years of the All of Us Research Program (AoURP) Illinois Precision Medicine Consortium (IPMC) award has created an impetus for precision health collaboration in Illinois that will leave a positive legacy for decades both locally and nationally. During the first 5 years of enrollment, the IPMC has drawn strength from our institutional differences, varied scientific interests and expertise, broad geographic catchment areas, and diverse patient populations. To date, we have enrolled a cohort of nearly 43,000 participants from Chicago and greater Illinois, accounting for nearly 10% of the core AoURP participants nationwide – exceeding all expectations for diversity through high enrollment (87%) of those underrepresented in biomedical research (UBR), despite a decreasing trend nationally. Through the COVID-19 pandemic, the IPMC has proven that we can evolve and thrive in a new research context, pivoting operationally while ensuring representation. This is important as the AoURP seeks new target populations (i.e., pediatric) and implementation approaches. The experience of leading the AoURP in Illinois has generated insights, knowledge, best practices, new ideas, and partners to continue and build upon our work in Chicago and throughout Illinois. This includes a recognition of the crucial role that authentic and longstanding engagement plays in developing inclusive biomedical research. We now have fully developed (and constantly expanding) clinical and community infrastructure, stakeholder buy-in, and integrated workflows. These will continue to guide IPMC performance and implementation strategies, supported by intentional engagement investment and integrated expertise. We have identified new scientific partnerships at our Health Provider Organizations (HPOs) and MPIs, now including an additional minority serving institution (MSI) with significant UBR engagement expertise. The IPMC offers this proposal, to fulfill or exceed the AoURP requirements for OTA-22-006 Areas of Interest (AOIs). Under the direction of the AoURP and NIH, for AOI 1- Community, Participant and Provider Engagement, Enrollment and Retention, we will work with AoURP leadership and stakeholders nationally and IPMC-wide to engage and recruit a targeted 50,000 diverse core participants in Illinois during the 5-year award period. We plan to recruit at least 85% UBR into the AoURP by leveraging established leadership and frontline teams, infrastructure, workflows, and new engagement partnerships. We will work collectively to achieve the engagement, enrollment, and retention (active and passive) milestones outlined by the AoURP and implement the protocol fully and flexibly as national approaches, milestone priorities, and strategies and priorities evolve. To achieve these aims, the IPMC proposes to maintain our HPO institutional membership (University of Chicago, Northwestern University, University of Illinois Chicago, NorthShore University HealthSystem, and Rush University, with subcontracts at University of Illinois Urbana-Champaign and University of Illinois Peoria) with Dr. Habibul Ahsan serving as the contact PI with MPIs Daviglus, Greenland, Aschebrook, Ho, Shah, Sanders, Pirzada, and Soares. We will also add a crucial engagement partnership with Governors State University, an MSI with Drs. Balthazar and Roberson joining as MPIs. Over the last 5 years, IPMC partners have demonstrated complementary reach into diverse patient populations while balancing key AoURP metrics (UBR engagement, high quality data, enrollment, and retention). We are confident that our 5-year plan will bring significant value to the AoURP, with an engaged and diverse participant population based in Illinois that will ultimately enable discovery and promote equity in the communities we collectively serve and beyond.", "keywords": [ "Acceleration", "Accounting", "Adult", "Age", "All of Us Research Program", "Amber", "Area", "Arthritis", "Automobile Driving", "Award", "Awareness", "Biomedical Research", "COVID-19 pandemic", "Catchment Area", "Cessation of life", "Chicago", "Childhood", "Church", "Clinical", "Clinical Informatics", "Collaborations", "Collection", "Communities", "Community Health", "Complex", "Computers", "Coronary heart disease", "Data", "Dedications", "Dementia", "Disease", "Education", "Electronic Health Record", "Electronic Mail", "Enrollment", "Ensure", "Environmental Exposure", "Equity", "Ethnic Origin", "Ethnic Population", "Evaluation", "Event", "Family", "Friends", "Funding", "Genetic", "Genomics", "Geography", "Goals", "Graduate Education", "Greenland", "Hand", "Health", "Health Personnel", "Health Sciences", "Health Service Area", "Health Technology", "Health care facility", "Health system", "Healthcare", "Healthcare Systems", "Hour", "Human", "Illinois", "Income", "Indiana", "Infrastructure", "Institution", "Internet", "Investments", "Knowledge", "Leadership", "Link", "Longevity", "Malignant Neoplasms", "Methods", "Minority Groups", "Minority-Serving Institution", "Modality", "Municipalities", "Observational epidemiology", "Operations Research", "Participant", "Patients", "Pediatrics", "Performance", "Persons", "Physicians", "Play", "Population", "Population Heterogeneity", "Positioning Attribute", "Precision Health", "Prevention", "Protocols documentation", "Provider", "Race", "Research", "Research Activity", "Research Personnel", "Residential Facilities", "Resources", "Role", "Rural", "Rural Population", "Saliva", "Schools", "Science", "Scientist", "Services", "Site", "Source", "Stroke", "Structure", "Students", "System", "Target Populations", "Telephone", "Text Messaging", "Training", "Training Programs", "United States", "United States National Institutes of Health", "Universities", "Voice", "Work", "career", "clinical phenotype", "clinical research site", "cohort", "community organizations", "community partnership", "cultural competence", "data exchange", "data quality", "demographics", "digital", "digital technology", "disability", "disparity reduction", "empowerment", "epidemiology study", "equity diversity and inclusion", "expectation", "experience", "flexibility", "follow-up", "health disparity", "health equity", "human disease", "implementation strategy", "improved", "innovation", "insight", "interest", "interope" ], "approved": true } }, { "type": "Grant", "id": "12270", "attributes": { "award_id": "1R01HS029340-01A1", "title": "The role of telehealth in improving access to and costs of unscheduled care among lower-income individuals", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Agency for Healthcare Research and Quality (AHRQ)" ], "program_reference_codes": [], "program_officials": [ { "id": 22615, "first_name": "Brent", "last_name": "Sandmeyer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-30", "end_date": "2027-07-31", "award_amount": 397212, "principal_investigator": { "id": 28162, "first_name": "Lindsay", "last_name": "Allen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 924, "ror": "", "name": "NORTHWESTERN UNIVERSITY AT CHICAGO", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "Immediate (or “urgent”) care treats injuries or illnesses that lie between primary and emergency care. During the COVID-19 pandemic, virtual immediate care made up the largest share of visits in the new, expanded telehealth infrastructure. The rise of virtual immediate care has important implications for health care access and costs, especially among those with Medicaid. Access to and costs associated with immediate care are especially important considerations for this marginalized group, who are less likely to engage in primary care, rely more heavily on expensive emergency department care for non-urgent conditions, and use more immediate care than those with higher incomes. Though virtual care is widely thought to increase care access and reduce costs, there are well-documented reasons to believe that these benefits might be offset among Medicaid enrollees. For example, those with lower incomes are less likely to have broadband access, rendering virtual care largely inaccessible. When it comes to spending, shifting urgent care visits away from the emergency department represents an important cost-savings opportunity. However, telehealth visits may also increase costs, by acting as a complement to in-person care, rather than a substitute, and by inducing new demand that otherwise would not have occurred. Further complicating the picture, the impact of virtual immediate care on access and costs likely differs across different types of telehealth models, and across different marginalized subpopulation (e.g., those living in rural areas, racial and ethnic minority groups, individuals with special health care needs, and women). To date, no study has measured the impact of virtual immediate care among Medicaid enrollees. Yet, as the public health emergency draws to a close in May 2023, state Medicaid agencies face important decisions on whether to permanently extend COVID-era telehealth policies. Our study’s purpose is to generate urgently- needed evidence to inform the policy conversation regarding telehealth and Medicaid, curating results that will be immediately useful to policy-makers. Using a mixed-methods approach, we will conduct quantitative analyses using extensive health record data from major health care systems across three states, followed by stakeholder interviews with both Medicaid administrators and health systems leaders. Our aims are 1) Measure the impact of different telehealth delivery models on immediate care access and use among low-income individuals, overall and by subpopulations; 2) Calculate the impact of different virtual immediate care delivery models on health care episode costs, accounting for downstream care and new health care use that would not have otherwise occurred, overall and by subpopulations; 3) Conduct semi-structured interviews with Medicaid administrators and health system leaders to transform study results into practicable knowledge for policymakers.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "12271", "attributes": { "award_id": "1R21AI175795-01", "title": "Live-cell imaging of SARS-CoV-2 replication organelle formation and RNA synthesis", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 27781, "first_name": "Mary Katherine Bradford", "last_name": "Plimack", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-15", "end_date": "2025-08-31", "award_amount": 195800, "principal_investigator": { "id": 28163, "first_name": "Zandrea", "last_name": "Ambrose", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "SARS-CoV-2 is a novel b-coronavirus identified in 2019 that causes the disease COVID-19, which is responsible for over 6 million deaths since late 2019. While recent virology studies have clarified many aspects of how SARS- CoV-2 infects cells and causes disease, questions remain on the spatio-temporal processes of post-entry replication steps, which may be useful for targeting novel therapies. Using reverse genetics and live cell and super-resolution microscopy of labeled SARS-CoV-2 proteins expressed in cells or during SARS-CoV-2 infection, we propose two aims to gain better understanding of virus-host interactions during infection of human airway cells. We will understand the role of host proteins in the biogenesis of SARS-CoV-2-induced double- membraned vesicles (Aim 1) and visualize the origin and trafficking of SARS-CoV-2 RNA synthesis (Aim 2) for WT virus and variants of concern (e.g., Alpha, Delta, and Omicron). The studies will be performed in real-time in human airway epithelial cell lines and deidentified primary cells. These aims will be performed by fluorescently labeling SARS-CoV-2 proteins and the viral RNA as well as host cell proteins. Small molecules, knock down of host factors, and mutations in the viral genome (including those found in highly circulating variants) will be used to alter these processes and, thus, infectivity to study replication mechanisms. In addition, correlative light- electron microscopy (CLEM) will provide structural information on these replication processes. Improved understanding of SARS-CoV-2 infection may lead to more effective COVID-19 therapies for infected individuals and could prepare us for preventing or treating new coronaviruses that arise in the future.", "keywords": [ "2019-nCoV", "Acute respiratory infection", "Biogenesis", "Biological", "Biological Assay", "COVID-19", "COVID-19 mortality", "COVID-19 prevention", "COVID-19 treatment", "Cell Line", "Cell membrane", "Cells", "Cellular biology", "Cessation of life", "Chiroptera", "Complex", "Confocal Microscopy", "Coronavirus", "Cytoplasm", "Disease", "Electron Microscopy", "Endoplasmic Reticulum", "Evaluation", "Future", "Genes", "Genetic Transcription", "Genome", "HIV-1", "Human", "Image", "Immune response", "Impaired cognition", "Individual", "Infection", "Integration Host Factors", "Investigation", "Label", "Lead", "Length", "Light", "Membrane", "Messenger RNA", "Methods", "Middle East Respiratory Syndrome Coronavirus", "Molecular", "Molecular Virology", "Mutation", "Nonstructural Protein", "Organelles", "Pathway interactions", "Peer Review", "Peptide Hydrolases", "Pneumonia", "Polyproteins", "Prevention", "Process", "Proteins", "Publications", "RNA", "RNA chemical synthesis", "Replication-Associated Process", "Research", "Role", "SARS coronavirus", "SARS-CoV-2 infection", "SARS-CoV-2 variant", "Symptoms", "Time", "Translating", "Translations", "Universities", "Vaccines", "Variant", "Vesicle", "Viral", "Viral Genome", "Virion", "Virulent", "Virus", "Virus Replication", "Visualization", "airway epithelium", "betacoronavirus", "cell fixing", "genomic RNA", "human coronavirus", "improved", "insight", "knock-down", "live cell imaging", "new therapeutic target", "nonsynonymous mutation", "novel", "novel coronavirus", "post SARS-CoV-2 infection", "prevent", "protein expression", "receptor binding", "reverse genetics", "small molecule", "spatiotemporal", "superresolution imaging", "superresolution microscopy", "trafficking", "transmission process", "ultra high resolution", "variants of concern", "viral RNA", "virology", "virus host interaction" ], "approved": true } }, { "type": "Grant", "id": "12272", "attributes": { "award_id": "1R21MD019394-01", "title": "Pandemic preparedness for underserved persons in the US: Harnessing data from the RADx-UP consortium to assess public health tools for resource allocation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 6025, "first_name": "Crystal", "last_name": "Barksdale", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-21", "end_date": "2025-06-30", "award_amount": 231600, "principal_investigator": { "id": 22265, "first_name": "Shuchi", "last_name": "Anand", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22266, "first_name": "GLENN MATTHEW", "last_name": "CHERTOW", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28082, "first_name": "Julie", "last_name": "Parsonnet", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Pandemic preparedness requires strengthening surveillance for emerging viruses, but also a plan for public health response when the next pathogen rapidly infects humans on a global scale. In order to ensure that the disproportionate disability and death experienced among disadvantaged populations in the US does not repeat in a future pandemic, public health agencies will need to validate resource allocation and surveillance tools within a health disparities framework. The RADx-UP Consortium enables such as an evaluation, since this NIH-funded Consortium of over 130 projects, with over 370,000 nationwide participants, focused on improving test access, and eliciting COVID19 stress and vaccine perception among underserved persons. Using RADx- UP data as the ground truth, we will test whether three area level vulnerability indices—the Social Vulnerability Index, the Minority Health Social Vulnerability Index, and the Community Vulnerability Index—identify persons experiencing food or housing insecurity, or gaps in healthcare access during the pandemic (Aim 1). We will leverage methods from clinical trial literature to assess RADx-UP data generalizability. We will link to American Community Survey, and generate county-standardized estimates of pandemic stress and vaccine concerns for the more than 900 US counties with participants in the RADx-UP consortium. We will then assess the association of these standardized estimates with the three area level vulnerability indices. A second aim of the proposed work will be to assess the predictive performance of the promising tool of wastewater surveillance among underserved populations. We will link RADx-UP data with the publicly available National Wastewater Surveillance System data, and compare wastewater infection prevalence metrics with the test positivity rate among RADx-UP performed tests, and county-level hospitalizations and deaths. We will evaluate changes in predictive performance over time (e.g., before versus after vaccine availability), and with integration of area- level vulnerability indices and other census demographic variables. With the ultimate aim of reducing health disparities in the future pandemic, our team of epidemiologists, statisticians, nephrology and infectious disease clinicians, and health policy experts will evaluate existing and emerging pandemic preparedness tools. In doing so, we hope to promote a public health infrastructure responsive to groups most vulnerable to the health and social turbulence inherent to a pandemic.", "keywords": [ "2019-nCoV", "Acceleration", "Age", "American", "American Indians", "Area", "Black race", "COVID-19", "COVID-19 pandemic", "COVID-19 stress", "COVID-19 test", "COVID-19 testing", "COVID-19 vaccine", "Censuses", "Centers for Disease Control and Prevention (U.S.)", "Cessation of life", "Chronic Disease", "Classification", "Clinical Trials", "Communicable Diseases", "Communities", "Community Surveys", "County", "Data", "Diagnostic", "Dialysis procedure", "Disease", "Disease Outbreaks", "Disparity population", "Ebola", "Employment", "Epidemiologist", "Ethnic Origin", "Evaluation", "Face", "Food", "Funding", "Future", "Goals", "Health", "Health Insurance", "Health Policy", "Health system", "Hispanic", "Hospitalization", "Household", "Housing", "Human", "Incidence", "Income", "Infection", "Influenza", "Influenza A Virus H1N1 Subtype", "Infrastructure", "Investments", "Link", "Literature", "Location", "Methods", "Middle East Respiratory Syndrome", "Monkeypox", "Neighborhoods", "Nephrology", "Outcome", "Participant", "Patients", "Perception", "Performance", "Persons", "Phase", "Population", "Positive Test Result", "Pragmatic clinical trial", "Prevalence", "Public Health", "Public Health Practice", "Race", "Reduce health disparities", "Resource Allocation", "Resources", "Sampling", "Severe Acute Respiratory Syndrome", "Severity of illness", "Site", "Speed", "Standardization", "Stress", "System", "Test Result", "Testing", "Time", "Traction", "Triage", "Uncertainty", "Underserved Population", "United States National Institutes of Health", "Vaccination", "Vaccines", "Virus", "Vulnerable Populations", "Work", "ZIKA", "data structure", "disability", "evidence base", "experience", "future pandemic", "health care availability", "health disparity", "home test", "hospitalization rates", "improved", "improved outcome", "indexing", "medical vulnerability", "minority health", "mortality", "new pandemic", "operation", "pandemic disease", "pandemic preparedness", "pandemic stress", "pathogen", "performance tests", "population survey", "predictive test", "public health emergency", "recruit", "response", "screening", "secondary analysis", "sex", "social", "social vulnerability", "socioeconomics", "stressor", "testing access", "testing uptake", "tool", "uptake", "vaccine access", "vulnerable community", "wastewater surveillance" ], "approved": true } }, { "type": "Grant", "id": "12273", "attributes": { "award_id": "1R43AI170278-01A1", "title": "New target and new therapy for severe Covid-19 and viral hyperinflammation damage: renalase and renalase agonists", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6115, "first_name": "DIPANWITA", "last_name": "Basu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-07", "end_date": "2025-08-31", "award_amount": 299999, "principal_investigator": { "id": 28164, "first_name": "BARRY A", "last_name": "BERKOWITZ", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 28165, "first_name": "Gary V.", "last_name": "Desir", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2079, "ror": "", "name": "BESSOR PHARMA, LLC", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The SARS-CoV-2 host response is associated with wide-ranging immuno-inflammatory derangements and tissue injury. We are developing an innovative therapeutic, BP-1002, to both blunt inflammatory cytokines and protect tissues. BP-1002 has the potential to prevent organ injury and deaths from COVID-19, regardless of viral variants. BP-1002, is a renalase (RNLS) agonist - a recently discovered secretory protein that promotes cell survival and downregulates the inflammatory response by signaling through the plasma-membrane calcium-ATPase, ATP2B4 (PMCA4b) receptor, and activating growth and survival pathways (protein kinase B, JAK/STAT, and MAP kinase). This activity is contained in a 20-40 amino acid RNLS site. Because RNLS is a large protein complex requiring manufacturing, we designed and developed BP-1002, a proprietary 36−aa RNLS-based (97.3 % amino acid identity) that contains the RNLS activity site. This RNLS agonist is stable and easily manufactured using chemical synthesis. Preliminary data show that low plasma RNLS correlates with disease severity hospitalized COVID-19 patients; or in acute renal injury, cardiac injury, and pancreatitis, which are COVID- 19 complications. Also, BP-1002 blunted inflammatory cytokine production (IL6, TNFα and IL1β) in human blood exposed ex vivo to the S- and M-proteins of SARS-CoV-2; improved survival by 60% in mouse models of simulated viral disease (poly(I:C) or SARS-CoV-2 infection). BP-1002 or recombinant RNLS reduced cell and tissue injury through modulation of inflammation, preservation of vascular integrity, and apoptosis prevention. Additionally, in a mouse inflammation model, single doses of BP-1002 had activity lasting 6 (intravenous) or 10 (subcutaneous) hours. Further, chronic-dosing pharmacology studies in mice show a profile consistent with a desirable therapeutic index. These studies confirm the strong potential for BP- 1002 as a new therapeutic for COVD-19. BP-1002 may also be useful alone or in combination with other COVID-19 therapies. A candidate for testing is IL-6 inhibitors, which have shown varied benefits for COVID-19 therapy. We plan further proof of concept evaluation of BP-1002, alone or with potentially synergistic IL-6 inhibition, to blunt inflammatory cytokines, prevent tissue damage and death in several mouse COVID-19 models. In addition, we will compare the pharmacokinetics after 30-min infusion, the route of administration that will be used in patients, with those after a dose-response studies after SC admin using a viral mouse model. Lastly, additional analytical studies will allow specifications to be set for future production.", "keywords": [ "2019-nCoV", "Active Sites", "Acute", "Adrenal Cortex Hormones", "Agonist", "Amino Acids", "Animal Model", "Anti-Inflammatory Agents", "Antiinflammatory Effect", "Apoptosis", "Biological Assay", "Blood", "Blood Vessels", "Body Weight decreased", "COVID-19", "COVID-19 complications", "COVID-19 morbidity", "COVID-19 mortality", "COVID-19 patient", "COVID-19 severity", "COVID-19 therapeutics", "COVID-19 treatment", "Cell Death", "Cell Survival", "Cessation of life", "Chronic", "Data", "Dose", "Dose Limiting", "Drug Kinetics", "Enzyme-Linked Immunosorbent Assay", "Equilibrium", "Evaluation", "Exposure to", "Freezing", "Future", "Growth", "Health", "Heart Injuries", "High Pressure Liquid Chromatography", "Histopathology", "Hospitalization", "Hour", "Human", "IL-6 inhibitor", "IL6 gene", "Immune response", "Immunologics", "Inflammation", "Inflammatory", "Inflammatory Infiltrate", "Inflammatory Response", "Influenza", "Influenza A Virus H1N1 Subtype", "Infusion procedures", "Injury", "Injury to Kidney", "Integration Host Factors", "Interleukin-1 beta", "Interleukin-6", "Intravenous", "Intravenous infusion procedures", "Kidney", "Length", "Lung", "Measurement", "Mitogen-Activated Protein Kinases", "Modeling", "Mus", "Onset of illness", "PMCA1 protein", "Pancreatitis", "Pathway interactions", "Patients", "Peptides", "Pharmaceutical Preparations", "Pharmacology Study", "Plasma", "Poly I-C", "Pre-Clinical Model", "Prevention", "Production", "Proteins", "Proto-Oncogene Proteins c-akt", "Publishing", "Rattus", "Recombinants", "Rodent", "Route", "SARS-CoV-2 immune response", "SARS-CoV-2 infection", "Severities", "Severity of illness", "Shapes", "Signal Transduction", "Site", "Spanish flu", "Specific qualifier value", "TNF gene", "Technology", "Temperature", "Testing", "Therapeutic", "Therapeutic Index", "Therapeutic Uses", "Time", "Tissues", "Toxic effect", "UV Radiation Exposure", "Vaccines", "Variant", "Viral", "Viral Load result", "Virus", "Virus Diseases", "cell injury", "chemical synthesis", "cytokine", "cytokine release syndrome", "design", "humanized mouse", "improved", "in vivo", "innovation", "kidney cell", "manufacture", "mortality", "mouse model", "multiple myeloma M Protein", "new therapeutic target", "novel", "novel therapeutics", "organ injury", "pre-clinical", "preservation", "prevent", "protein complex", "receptor", "response", "secretory protein", "severe COVID-19", "side effe" ], "approved": true } }, { "type": "Grant", "id": "12274", "attributes": { "award_id": "1R43IP001229-01A1", "title": "PA21259, SBIR Phase I, Developing a RIG-I agonist to prevent COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2023-09-30", "end_date": "2024-07-01", "award_amount": 299984, "principal_investigator": { "id": 28166, "first_name": "Bryan", "last_name": "Berube", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1031, "ror": "", "name": "HDT BIO CORPORATION", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Project summary: Despite widespread availability of vaccines, the SARS-CoV-2 pandemic continues to wreak havoc on our healthcare system and our economy. High numbers of unvaccinated individuals combined with vaccine breakthrough cases continues to allow the virus to spread throughout the community and cause morbidity and mortality at high rates. There continues to be an urgent need for innovative therapeutics to address the current pandemic, as well as those which will inevitably arise in the future. Host-directed therapies (HDTs) offer a promising approach in this regard. Rather than targeting the virus itself, HDTs target the host to either restrict an essential growth factor or upregulate innate defenses. By targeting the host to attack the virus, traditional mechanisms of antiviral resistance are circumvented. We are developing a broad-spectrum antiviral RNA molecule targeting retinoic acid inducible gene-I (RIG-I), a host pattern recognition receptor (PRR) evolved to recognize viral RNA to trigger innate antiviral immune responses, an approach validated in preclinical studies to protect mice from multiple RNA and DNA viruses. Our preliminary data show the RIG-I agonist, PAMP105, prevents SARS-CoV-2 replication in vitro and can be effectively delivered to the lung to completely prevent disease from influenza and SARS-CoV-2 infection. In the proposed studies herein, we will perform critical formulation optimization to create a final product to be tested for efficacy against SARS- CoV-2 challenge in vitro and in vivo. We will optimize parameters of four clinically relevant nanoparticle formulations, including our novel nano-structured lipid carrier, which effectively protects and delivers RNA in vivo. We will optimize formulation parameters and downselect a final formulation by measuring cytokine release patterns in vivo from the blood, lung, and liver following innate immune agonist delivery. The lead formulated PAMP molecule will be tested for efficacy against a SARS-CoV-2 challenge in Syrian hamsters. To this point, little progress has been made clinically in developing innate immune agonists as therapeutics. Our expertise formulating agonists and vaccine platforms (including RNA) for preclinical and clinical trials will allow us to use a variety of nanoparticle formulations to deliver this RNA RIG-I agonist safely and effectively in a pressurized metered-dose inhaler to treat SARS-CoV-2 infection following exposure or after symptom onset. With results from this Phase I project, we will advance our formulated host-directed RNA molecule into clinical development as a as part of our Phase II research. Once developed, our therapeutic can be quickly pivoted for use against any number of current or emerging viruses, including influenza, Hepatitis B Virus, Hepatitis C Virus, Dengue Virus, or West Nile Virus, all of which are susceptible to PAMP in preclinical studies.", "keywords": [ "2019-nCoV", "Address", "Adjuvant", "Agonist", "Animals", "Antiviral Agents", "Antiviral Response", "Antiviral resistance", "Bacterial Infections", "Binding", "Blood", "Blood Circulation", "COVID-19", "COVID-19 pandemic", "COVID-19 prevention", "COVID-19 treatment", "Cells", "Clinical", "Clinical Trials", "Communities", "Complement", "DNA Viruses", "Data", "Defensins", "Dengue Virus", "Development", "Diagnosis", "Disease", "Epidemiology", "Epithelial Cells", "Event", "Formulation", "Future", "Gene Expression", "Genes", "Goals", "Growth Factor", "Health system", "Healthcare Systems", "Hepatitis B Virus", "Hepatitis C virus", "Human", "Hybrids", "Immune", "Immune response", "In Vitro", "Individual", "Influenza", "Innate Immune Response", "Interferon alpha", "Intervention", "Lead", "Leadership", "Legal patent", "Lipids", "Liver", "Lung", "Measures", "Mesocricetus auratus", "Metered Dose Inhaler Device", "Molecular", "Morbidity - disease rate", "Mus", "Nanostructures", "Natural Immunity", "Nucleotides", "Pathway interactions", "Pattern", "Pattern recognition receptor", "Peptides", "Phase", "Production", "Prophylactic treatment", "RNA", "RNA Viruses", "Reagent", "Recovery", "Research", "Resistance", "Respiratory syncytial virus", "SARS-CoV-2 infection", "SARS-CoV-2 positive", "Signal Transduction", "Speed", "Symptoms", "Therapeutic", "Transfection", "Translating", "Tretinoin", "Vaccines", "Viral Load result", "Virus", "Virus Diseases", "Virus Replication", "West Nile virus", "adaptive immune response", "airway epithelium", "antimicrobial", "clinical development", "clinically relevant", "cytokine", "efficacy testing", "experience", "fighting", "in vivo", "influenza infection", "innovation", "microbial", "mortality", "nanoparticle", "new therapeutic target", "novel", "novel therapeutics", "pandemic disease", "pathogen", "post SARS-CoV-2 infection", "preclinical study", "preclinical trial", "pressure", "prevent", "product development", "programs", "protective efficacy", "receptor", "response", "sound", "structured lipid", "targeted treatment", "transcription factor", "transmission process", "unvaccinated", "vaccine access", "vaccine platform", "viral RNA" ], "approved": true } }, { "type": "Grant", "id": "12275", "attributes": { "award_id": "1R03HD112587-01", "title": "Identifying healthcare and telehealth access for people with hand spasticity", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 21015, "first_name": "TOYIN DELE", "last_name": "Ajisafe", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-20", "end_date": "2025-08-31", "award_amount": 77500, "principal_investigator": { "id": 28167, "first_name": "Rozina", "last_name": "Bhimani", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 764, "ror": "https://ror.org/017zqws13", "name": "University of Minnesota", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true }, "abstract": "The world we knew prior to the COVID-19 pandemic is unlikely ever to return. Structural and behavioral changes, such as remote working, socialization, and learning, are now part of everyday life. Telehealth has emerged as a solution for health care delivery, and social connections have been maintained through Zoom, Teams, and other software applications. These are good solutions for the general population, but people with hand spasticity may not be able to use electronic devices without assistance. Spasticity, a sequela of some neurological conditions, causes tight muscles, interferes with functional movements, affects activities of daily living (ADLs), and increases caregiver burden. Moderate to high levels of spasticity cause loss of independence and even institutionalization. The goal of spasticity care is to achieve optimal independence in all aspects of life, with the assistance of others and aid of technology only as needed; however, the degree to which individuals with moderate to high levels of hand spasticity can access and draw upon technology to maintain their independence is unknown. Therefore, this application responds to the notice of special interest to investigate the impact of COVID-19 on people with hand spasticity and identify current rehabilitation needs to inform future interventions. The long-term goal of this research is to support optimal independence for people with spasticity and good quality of life. The rationale for this exploratory sequential mixed-method study, which is guided by the socio-ecological model, is to determine the impact of telehealth access on the receipt of health care and the ability of adults with hand spasticity to maintain independence. Specific aims are to: Aim 1. Identify access to health care and telehealth for adults with moderate to high levels of hand spasticity in the community. Aim 2: Identify computer literacy and barriers and facilitators to accessing telehealth for adults living with moderate to high levels of hand spasticity in the community. Aim 3: Identify the extent to which telehealth access and computer literacy affect independence for adults living with moderate to high level of spasticity in the community. Approach. Thirty adults with moderate to high levels of hand spasticity living in the community will be recruited. NIH and PROMIS tools will assess Coronavirus Impact, access to technology, upper dexterity, physical functioning, ADLs and Instrumental ADLs, psychological impact, loneliness, and social and emotional health. Using the Coronavirus Impact and access to technology tools, we will first quantify the effect of the pandemic on health care, telehealth, and independence. Then we will conduct 45- to 60-minute semi- structured interviews that will offer greater insight into telehealth literacy, its barriers and facilitators, and its impact on maintaining independence. This study is significant because it pinpoints unaddressed Covid-related experiences and concerns affecting the ability of this population to maintain independence.", "keywords": [ "Activities of Daily Living", "Adult", "Affect", "Behavioral", "Brain Injuries", "COVID-19 impact", "COVID-19 pandemic", "Caregiver Burden", "Caring", "Cerebral Palsy", "Communities", "Computer Literacy", "Computer software", "Computers", "Coronavirus", "Data", "Disabled Persons", "Electronics", "Emotional", "Future", "General Population", "Goals", "Hand", "Health", "Health Services", "Health Technology", "Healthcare", "Individual", "Institutionalization", "Intervention", "Interview", "Learning", "Life", "Loneliness", "Methods", "Minnesota", "Mission", "Modeling", "Movement", "Multiple Sclerosis", "Muscle", "National Institute of Child Health and Human Development", "Neurologic", "Occupational Therapist", "Paralysed", "Personal Satisfaction", "Persons", "Physical Function", "Physicians", "Policies", "Population", "Prevention", "Principal Investigator", "Psychological Impact", "Public Health", "Quality of life", "Rehabilitation Nursing", "Rehabilitation therapy", "Research", "Research Personnel", "Socialization", "Spinal cord injury", "Statistical Data Interpretation", "Stroke", "Structure", "Technology", "United States National Institutes of Health", "Upper Extremity", "Veterans", "Work", "clinical practice", "dexterity", "disability", "experience", "health care availability", "health care delivery", "health literacy", "improved", "innovation", "insight", "instrumental activity of daily living", "interest", "literacy", "pandemic disease", "pandemic impact", "physically handicapped", "post stroke", "recruit", "social", "societal costs", "spasticity", "telehealth", "tool" ], "approved": true } }, { "type": "Grant", "id": "12276", "attributes": { "award_id": "1R13CA278261-01", "title": "Cancer Center Survivorship Research Forum", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 24581, "first_name": "Michelle A", "last_name": "Mollica", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-18", "end_date": "2024-08-31", "award_amount": 12500, "principal_investigator": { "id": 28168, "first_name": "Anne H.", "last_name": "Blaes", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 28169, "first_name": "Lidia", "last_name": "Schapira", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 764, "ror": "https://ror.org/017zqws13", "name": "University of Minnesota", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true }, "abstract": "The goal of this proposed biennial survivorship symposium series is to improve cancer outcomes by creating a regular forum for researchers, clinicians, and survivors to share cutting-edge research and foster new collaborations, research, programs, and policies. One of the defining features of cancer survivorship care — at the same time a strength and a challenge — is its multidimensional nature. The needs of cancer survivors are complex, spanning both oncologic and other physical concerns (e.g., cardiovascular treatment sequelae), psychosocial concerns, and practical concerns (e.g., financial burdenfrom medical expenses that affect the whole family). Addressing these concerns and focusing on the best ways to deliver cancer survivorship care requires close and careful collaboration between experts from multiple fields. The discontinuation of the Biennial Cancer Survivorship Research conferences in 2016 left a gap in cancer survivorship care. The proposed biennial symposium will fill this gap by facilitating knowledge exchange and sustained collaborations and networking among researchers and clinicians from multiple disciplines, with additional input from patient perspectives, and by identifying and formulating future directions of survivorship research with a focus on equitable healthcare delivery. The first conference, held virtually during the COVID-19 pandemic, was hosted by the University of Minnesota in April 2021 and was well attended. The second conference is planned for September of 2023 at Stanford University. With the title of “Implementing Equitable Survivorship Care Across the Life Span”, we aim to bring pertinent and cutting-edge research topics in the field of cancer survivorship to a global community of diverse stakeholders. Topics will include the circle of survivorship care in standardization, risk stratification, and implementation; implementing precision risk-stratified survivorship care; priorities for survivorship research: global solutions to common challenges; and translating innovation into clinical practice with a focus on diverse patient populations across academic and community practices. Conference Plan", "keywords": [ "Acceleration", "Address", "Advocate", "Affect", "American Cancer Society", "American Society of Clinical Oncology", "Anxiety", "Attention", "Awareness", "COVID-19 pandemic", "Cancer Center", "Cancer Patient", "Cancer Survivor", "Cancer Survivorship", "Cardiovascular system", "Caregivers", "Caring", "Chronic Disease", "Clinical", "Collaborations", "Communities", "Community Clinical Oncology Program", "Community Practice", "Complex", "Country", "Dimensions", "Discipline", "Effectiveness", "Enhancement Technology", "Epidemiology", "Equitable healthcare", "Equity", "Faculty", "Family", "Fostering", "Fright", "Future", "Future Teacher", "General Practitioners", "Generations", "Goals", "Health Personnel", "Health Service Area", "Health Services Research", "Healthcare", "Individual", "Institution", "Insurance", "Knowledge", "Left", "Long-Term Care", "Longevity", "Malignant Neoplasms", "Medical", "Mentors", "Mentorship", "Metabolic syndrome", "Minnesota", "Mission", "National Cancer Institute", "Nature", "Outcome", "Patients", "Peer Review", "Physicians", "Policies", "Population", "Professional Organizations", "Program Development", "Psychosocial Assessment and Care", "Publications", "Research", "Research Personnel", "Rotation", "Science", "Second Primary Cancers", "Self Management", "Series", "Service delivery model", "Services", "Shapes", "Site", "Specialist", "Standardization", "Stress", "Survivors", "Time", "Translating", "United States", "Universities", "Work", "baby boomer", "cancer care", "cancer diagnosis", "cancer therapy", "cardiovascular risk factor", "care delivery", "catalyst", "clinical practice", "community engagement", "comorbidity", "design", "experience", "health care delivery", "implementation science", "improved", "innovation", "intergenerational", "meetings", "multidisciplinary", "novel", "patient oriented", "patient population", "programs", "psychosocial", "risk stratification", "social", "success", "survivorship", "symposium", "tool", "virtual" ], "approved": true } }, { "type": "Grant", "id": "12277", "attributes": { "award_id": "1R21HD112373-01", "title": "Cognitive strategy training in Post-COVID-19 Syndrome: A feasibility trial.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 26611, "first_name": "Susan F.", "last_name": "Marden", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-19", "end_date": "2025-08-31", "award_amount": 430375, "principal_investigator": { "id": 28170, "first_name": "Anna", "last_name": "Boone", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 28171, "first_name": "Timothy J.", "last_name": "Wolf", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1049, "ror": "", "name": "UNIVERSITY OF MISSOURI-COLUMBIA", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "The long-term goal of this project is to help improve recovery from cognitive impairment associated with post- COVID-19 syndrome (PCS). PCS cognitive symptoms require the rehabilitation community to investigate ways to: (1) reduce the functional impact of the symptoms on daily life and (2) support individuals with PCS to establish new habits to improve and maintain health. The research hypothesis is that an activity-based metacognitive-strategy training intervention, the Cognitive Orientation to daily Occupational Performance (CO- OP) approach can feasibly be administered remotely and will improve activity performance, cognitive function, and quality of life in individuals with PCS. The specific aims of this study are to assess the: (1) feasibility of delivering CO-OP remotely to individuals with PCS in preparation for a future R01 trial; and (2) effect of CO-OP on activity performance, subjective and objective cognitive function, and quality of life in a sample of individuals with PCS as compared to an inactive control group. Specific aims will be completed through a single-blind, parallel, exploratory, randomized controlled trial. Individuals with PCS will be identified and asked to complete a prescreening survey to evaluate eligibility. Those meeting eligibility will undergo a baseline assessment battery. Participants (n=65) will then be randomized to a remote CO-OP treatment group (45 minutes per week for 10 weeks) or to an inactive control group. A post-intervention assessment will be completed immediately following the intervention. The purpose of this R21 is to evaluate feasibility outcomes and to obtain estimates of effect and precision of response on the outcome measures. To explore the effects of dosage on the primary outcome of activity performance, the biweekly COPM ratings will be plotted against time. Independent samples t-test and chi square test will be used to investigate differences among the two study arms and to assess whether randomization was successful. Descriptive statistics will be calculated for demographic information and the measures of intervention acceptability. Pre-to-post change in each of the outcome measures will be calculated for both groups. Cohen’s d effect size reported with precision around the estimate, 95% confidence intervals, will be used to evaluate the within and between group effects of the interventions on the primary and secondary outcome measures. The expected outcomes of this study are: (1) data to support the feasibility of remotely administering CO-OP; and (2) data to estimate effect sizes and precision of estimates of the CO-OP intervention in PCS. These data will be important for planning a future clinical trial to confirm any effects. This proposal is timely and consistent with the research priority of the National Center for Medical Rehabilitation Research (NCMRR) to identify, prevent, and treat key secondary conditions (e.g. PCS); the research program area of chronic symptom management; and the NICHD Notice of Special Interest (NOT-HD-20-03) addressing rehabilitation needs of COVID-19 survivors.", "keywords": [ "Achievement", "Activities of Daily Living", "Address", "Area", "Attention", "Automobile Driving", "Back", "COVID-19", "COVID-19 impact", "COVID-19 long hauler", "COVID-19 pandemic", "COVID-19 survivors", "Chi-Square Tests", "Chronic", "Classification", "Client", "Clinical Trials", "Cognition", "Cognitive", "Communities", "Compensation", "Complex", "Confidence Intervals", "Control Groups", "Coronavirus Infections", "Data", "Economics", "Educational Intervention", "Eligibility Determination", "Etiology", "Evidence based practice", "Executive Dysfunction", "Family", "Foundations", "Future", "Goals", "Habits", "Health", "Impaired cognition", "Impairment", "Improve Access", "Individual", "Infection", "Intervention", "Learning", "Leisures", "Life", "Long COVID", "Long-Term Effects", "Measures", "Medical", "Medical center", "National Institute of Child Health and Human Development", "Neurobehavioral Manifestations", "Neurologic", "Occupational", "Occupational activity of managing finances", "Outcome", "Outcome Measure", "Outcome Study", "Participant", "Performance", "Persons", "Population", "Preparation", "Prevalence", "Problem Solving", "Protocols documentation", "Quality of life", "Randomized", "Randomized Controlled Trials", "Recommendation", "Rehabilitation therapy", "Reporting", "Research", "Research Priority", "SARS-CoV-2 infection", "Sample Size", "Sampling", "Self Management", "Single-Blind Study", "Stroke", "Structure", "Subgroup", "Surveys", "Symptoms", "Task Performances", "Testing", "Time", "Training", "Traumatic Brain Injury", "United States", "Work", "brain fog", "cancer-related cognitive impairment", "cognitive function", "cognitive performance", "cognitive recovery", "coronavirus disease", "dosage", "effective intervention", "executive function", "experience", "feasibility trial", "functional improvement", "improved", "improved outcome", "innovation", "interest", "intervention effect", "meetings", "mild traumatic brain injury", "negative affect", "novel", "persistent symptom", "post intervention", "prevent", "primary outcome", "programs", "recruit", "rehabilitation research", "rehabilitation service", "remote administration", "response", "screening", "secondary outcome", "statistics", "symptom management", "symptomatology", "treatment group", "two-arm study" ], "approved": true } }, { "type": "Grant", "id": "12278", "attributes": { "award_id": "1R35GM149335-01", "title": "Data-driven and science-informed methods for the discovery of biomedical mechanisms and processes", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 12060, "first_name": "Han", "last_name": "Nguyen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-25", "end_date": "2028-08-31", "award_amount": 348954, "principal_investigator": { "id": 28172, "first_name": "David", "last_name": "Bortz", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1583, "ror": "", "name": "UNIVERSITY OF COLORADO", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "Data-driven discovery methods are a novel class of methodologies and computational approaches, revolutionizing the modeling, prediction, and control of complex systems, while remaining scienti cally explainable and interpretable. These methods learn governing equations directly from data and have found considerable success in a wide range of applications including turbulence, climate, robotics, and autonomy. However, the rst generation of these methods has proven poorly suited to the study of biomedical data. To realize the full potential of data-driven approaches, they must be extended and adapted to deal with the noise, sparsity, and variability intrinsic to experiments with living organisms. My group has extended the seminal Sparse Identi cation of Nonlinear Dynamics (SINDy) method to the Weak form SINDy (WSINDy). Weak form equations are a transform of the original data that enables learning of the equations even in the presence of substantial noise and sparsity. The approach eectively recasts scienti c discovery from proposing and validating/refuting a single scienti c hypothesis to simultaneously proposing (in many cases) more than 10180 hypotheses and using sparse regressing to prune the hypotheses which are not supported by the data. Moreover, our approach currently takes on the order of minutes on a standard laptop. The overarching goals of this research are to use the WSINDy method to investigate the 1) individual cell-based drivers for collective cell migration and 2) data-driven inference for unobserved processes in infectious disease dynamics as well as 3) extend WSINDy to infer stochastic dynamical systems and discover critical, but hidden, compartments. The rst goal continues a long collaboration with Xuedong Liu (CU-Boulder). We have adapted WSINDy to create individualized models of each cell in a migrating colony. We learn the interaction rules and can classify them according to cell type. The plan is to continue expanding the capabilities of WSINDy in this context to hopefully learn the biochemical dynamics unique to each cell. This would be the rst coupling of data-driven models for inter- and intra-cell processes. It will lead us closer to understanding how cells make decisions that lead to the emergent collective motion in wound healing. The second goal expands a collaboration with Beth Carlton (an epidemiologist) in infectious disease dynamics centered around the COVID-19 modeling team (of which we are both members). During our eorts to develop a compartmental model for advising the State Epidemiologist and the Governor, several questions arose that could be e ciently answered by extensions to WSINDy. In particular, we will develop data-driven inference for infection and recovery rates as well as the distribution of dwell times in the infection timeline. The last goal involves extensions of WSINDy to learn models for situations that frequently arise in biomedical phenomenon. First, we plan to learn stochastic dynamical system. Previous eorts were only able to infer either drift term or mean eld equations. By recasting WSINDy to evaluate moments of the data, we can learn the stochastic models directly. Lastly, inference regarding unobserved compartments is challenging, but via an extension to WSINDy we plan to discover unobserved variables and their equations.", "keywords": [ "Biochemical", "Biological", "COVID-19", "Cations", "Cells", "Classification", "Climate", "Collaborations", "Communicable Diseases", "Complex", "Coupling", "Data", "Decision Making", "Epidemiologist", "Equation", "Generations", "Goals", "Individual", "Infection", "Lead", "Learning", "Methodology", "Methods", "Modeling", "Motion", "Noise", "Nonlinear Dynamics", "Organism", "Process", "Recovery", "Research", "Robotics", "Science", "Seminal", "System", "cell motility", "cell type", "data-driven model", "dynamic system", "experimental study", "laptop", "learning strategy", "member", "migration", "novel", "success", "timeline", "wound healing" ], "approved": true } } ], "meta": { "pagination": { "page": 1384, "pages": 1424, "count": 14236 } } }